Last Updated: November 8, 2026

OCUFLOX Drug Patent Profile

« Back to Dashboard


Which patents cover Ocuflox, and when can generic versions of Ocuflox launch?

Ocuflox is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in OCUFLOX is ofloxacin. There is one drug master file entry for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the ofloxacin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ocuflox

A generic version of OCUFLOX was approved as ofloxacin by CHARTWELL RX on September 2nd, 2003.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for OCUFLOX?
  • What are the global sales for OCUFLOX?
  • What is Average Wholesale Price for OCUFLOX?
Summary for OCUFLOX
Recent Clinical Trials for OCUFLOX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Montefiore Medical CenterPhase 3
University of California, San FranciscoPhase 4
Winston Chamberlain, MD, PhDPhase 4

See all OCUFLOX clinical trials

Pharmacology for OCUFLOX

US Patents and Regulatory Information for OCUFLOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan OCUFLOX ofloxacin SOLUTION/DROPS;OPHTHALMIC 019921-001 Jul 30, 1993 AT RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OCUFLOX

See the table below for patents covering OCUFLOX around the world.

Country Patent Number Title Estimated Expiration
Austria 10282 ⤷  Start Trial
Australia 529263 ⤷  Start Trial
Australia 7487881 ⤷  Start Trial
Bosnia and Herzegovina 97190 ⤷  Start Trial
Canada 1167840 DERIVES DE BENZOXAZINE (BENZOXAZINE DERIVATIVES) ⤷  Start Trial
Germany 3167216 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OCUFLOX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0206283 SPC/GB97/085 United Kingdom ⤷  Start Trial PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
0206283 C980016 Netherlands ⤷  Start Trial PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
0206283 98C0041 Belgium ⤷  Start Trial PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0413455 98C0040 Belgium ⤷  Start Trial PRODUCT NAME: ALATROFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/060/001 19980327; FIRST REGISTRATION: CH 54484 19980327
1429780 13C0012 France ⤷  Start Trial PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780 SPC/GB12/058 United Kingdom ⤷  Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.